COVID-19–Associated Multisystem Inflammatory Syndrome in Children — United States, March–July 2020

Weekly / August 14, 2020 / 69(32);1074–1080

Print
Related Pages

On August 7, 2020, this report was posted online as an MMWR Early Release.

Please note: This report has been corrected. An erratum has been published.

Shana Godfred-Cato, DO1; Bobbi Bryant, MPH1,2; Jessica Leung, MPH1; Matthew E. Oster, MD1; Laura Conklin, MD1; Joseph Abrams, PhD1; Katherine Roguski, MPH1; Bailey Wallace, MPH1,2; Emily Prezzato, MPH1; Emilia H. Koumans, MD1; Ellen H. Lee, MD3; Anita Geevarughese, MD3; Maura K. Lash, MPH3; Kathleen H. Reilly, PhD3; Wendy P. Pulver, MS4; Deepam Thomas, MPH5; Kenneth A. Feder, PhD6; Katherine K. Hsu, MD7; Nottasorn Plipat, MD, PhD8; Gillian Richardson, MPH9; Heather Reid10; Sarah Lim, MBBCh11; Ann Schmitz, DVM12,13; Timmy Pierce, MPH1,2; Susan Hrapcak, MD1; Deblina Datta, MD1; Sapna Bamrah Morris, MD1; Kevin Clarke, MD1; Ermias Belay, MD1; California MIS-C Response Team (View author affiliations)

View suggested citation

Summary

What is already known about this topic?

Multisystem inflammatory syndrome in children (MIS-C) is a rare but severe condition that has been reported approximately 2–4 weeks after the onset of COVID-19 in children and adolescents.

What is added by this report?

Most cases of MIS-C have features of shock, with cardiac involvement, gastrointestinal symptoms, and significantly elevated markers of inflammation, with positive laboratory test results for SARS-CoV-2. Of the 565 patients who underwent SARS-CoV-2 testing, all had a positive test result by RT-PCR or serology.

What are the implications for public health practice?

Distinguishing MIS-C from other severe infectious or inflammatory conditions poses a challenge to clinicians caring for children and adolescents. As the COVID-19 pandemic continues to expand in many jurisdictions, health care provider awareness of MIS-C will facilitate early recognition, early diagnosis, and prompt treatment.

Article Metrics
Altmetric:
Citations:
Views:

Views equals page views plus PDF downloads

Metric Details
Figure
Tables

Table 1

Table 2

Related Materials

In April 2020, during the peak of the coronavirus disease 2019 (COVID-19) pandemic in Europe, a cluster of children with hyperinflammatory shock with features similar to Kawasaki disease and toxic shock syndrome was reported in England* (1). The patients’ signs and symptoms were temporally associated with COVID-19 but presumed to have developed 2–4 weeks after acute COVID-19; all children had serologic evidence of infection with SARS-CoV-2, the virus that causes COVID-19 (1). The clinical signs and symptoms present in this first cluster included fever, rash, conjunctivitis, peripheral edema, gastrointestinal symptoms, shock, and elevated markers of inflammation and cardiac damage (1). On May 14, 2020, CDC published an online Health Advisory that summarized the manifestations of reported multisystem inflammatory syndrome in children (MIS-C), outlined a case definition,† and asked clinicians to report suspected U.S. cases to local and state health departments. As of July 29, a total of 570 U.S. MIS-C patients who met the case definition had been reported to CDC. A total of 203 (35.6%) of the patients had a clinical course consistent with previously published MIS-C reports, characterized predominantly by shock, cardiac dysfunction, abdominal pain, and markedly elevated inflammatory markers, and almost all had positive SARS-CoV-2 test results. The remaining 367 (64.4%) of MIS-C patients had manifestations that appeared to overlap with acute COVID-19 (2–4), had a less severe clinical course, or had features of Kawasaki disease.§ Median duration of hospitalization was 6 days; 364 patients (63.9%) required care in an intensive care unit (ICU), and 10 patients (1.8%) died. As the COVID-19 pandemic continues to expand in many jurisdictions, clinicians should be aware of the signs and symptoms of MIS-C and report suspected cases to their state or local health departments; analysis of reported cases can enhance understanding of MIS-C and improve characterization of the illness for early detection and treatment.

Local and state health departments reported suspected MIS-C patients to CDC using CDC’s MIS-C case report form, which included information on patient demographics, clinical findings, and laboratory test results. Patients who met the MIS-C case definition and were reported to CDC as of July 29, 2020, were included in the analysis. Latent class analysis (LCA), a statistical modeling technique that can divide cases into groups by underlying similarities, was used to identify and describe differing manifestations in patients who met the MIS-C case definition. The indicator variables used in the LCA were the presence or absence of SARS-CoV-2–positive test results by reverse transcription–polymerase chain reaction (RT-PCR) or serology, shock, pneumonia, and involvement of organ systems (i.e., cardiovascular, dermatologic, gastrointestinal, hematologic, neurologic, renal, or respiratory). Three-class LCA was conducted using the R software package “poLCA” with 100 iterations to identify the optimal classification scheme (5). Clinical and demographic variables were reported for patients by LCA class. Chi-squared or Fisher’s exact tests were used to compare proportions of categorical variables; numeric variables, with medians and interquartile ranges, were compared using the Kruskal-Wallis rank sum test.

As of July 29, 2020, a total of 570 MIS-C patients with onset dates from March 2 to July 18, 2020, had been reported from 40 state health departments, the District of Columbia, and New York City (Figure). The median patient age was 8 years (range = 2 weeks–20 years); 55.4% were male, 40.5% were Hispanic or Latino (Hispanic), 33.1% were non-Hispanic black (black), and 13.2% non-Hispanic white (white) (Table 1). Obesity was the most commonly reported underlying medical condition, occurring in 30.5% of Hispanic, 27.5% of black, and 6.6% of white MIS-C patients.

Overall, the illness in 490 (86.0%) patients involved four or more organ systems. Approximately two thirds did not have preexisting underlying medical conditions before MIS-C onset. The most common signs and symptoms reported during illness course were abdominal pain (61.9%), vomiting (61.8%), skin rash (55.3%), diarrhea (53.2%), hypotension (49.5%), and conjunctival injection (48.4%). Most patients had gastrointestinal (90.9%), cardiovascular (86.5%), or dermatologic or mucocutaneous (70.9%) involvement. Substantial numbers of MIS-C patients had severe complications, including cardiac dysfunction (40.6%), shock (35.4%), myocarditis (22.8%), coronary artery dilatation or aneurysm (18.6%), and acute kidney injury (18.4%). The majority of patients (63.9%) were admitted to an ICU. The median length of ICU stay was 5 days (interquartile range = 3–7 days).

Of the 565 (99.1%) patients who underwent SARS-CoV-2 testing, all had a positive test result by RT-PCR or serology; 46.1% had only serologic evidence of infection and 25.8% had only positive RT-PCR test results. Five patients (0.9%) did not have testing performed but had an epidemiologic link as indicated in the MIS-C case definition.

Among all 570 patients, 527 (92.5%) were treated, including 424 (80.5%) who received intravenous immunoglobulin (IVIG), 331 (62.8%) who received steroids, 309 (58.6%) who received antiplatelet medication, 233 (44.2%) who received anticoagulation medication, and 221 (41.9%) who were treated with vasoactive medication. Ten (1.8%) patients were reported to have died (Table 1).

LCA identified three classes of patients, each of which had significantly different illness manifestations related to some of the key indicator variables. Class 1 represented 203 (35.6%) patients who had the highest number of involved organ systems. Within this group, 99 (48.8%) had involvement of six or more organ systems; those most commonly affected were cardiovascular (100.0%) and gastrointestinal (97.5%). Compared with the other classes, patients in class 1 had significantly higher prevalences of abdominal pain, shock, myocarditis, lymphopenia, markedly elevated C-reactive protein (produced in the liver in response to inflammation), ferritin (an acute-phase reactant), troponin (a protein whose presence in the blood indicates possible cardiac damage), brain natriuretic peptide (BNP), or proBNP (indicative of heart failure) (p<0.01) (Tables 1 and 2). Almost all class 1 patients (98.0%) had positive SARS-CoV-2 serology test results with or without positive SARS-CoV-2 RT-PCR test results. These cases closely resembled MIS-C without overlap with acute COVID-19 or Kawasaki disease.

Class 2 included 169 (29.6%) patients; among those in this group, 129 (76.3%) had respiratory system involvement. These patients were significantly more likely to have cough, shortness of breath, pneumonia, and acute respiratory distress syndrome (ARDS), indicating that their illnesses might have been primarily acute COVID-19 or a combination of acute COVID-19 and MIS-C. The rate of SARS-CoV-2 RT-PCR positivity (without seropositivity) in this group (84.0%) was significantly higher than that for class 1 (0.5%) or class 3 (2.0%) patients (p<0.01). The case fatality rate among class 2 patients was the highest (5.3%) among all three classes (p<0.01).

Class 3 included 198 (34.7%) patients; the median age of children in this group (6 years) was younger than that of the class 1 patients (9 years) or class 2 patients (10 years) (p<0.01) (Table 1). Class 3 patients also had the highest prevalence of rash (62.6%), and mucocutaneous lesions (44.9%). Although not statistically significant (p = 0.49), the prevalence of coronary artery aneurysm and dilatations (18.2%) was higher than that in class 2 patients (15.8%), but lower than that in class 1 patients (21.1%). Class 3 patients more commonly met criteria for complete Kawasaki disease (6.6%) compared with class 1 (4.9%) and class 2 (3.0%) patients (p = 0.30), and had the lowest prevalence of underlying medical conditions, organ system involvement, complications (e.g., shock, myocarditis), and markers of inflammation and cardiac damage. Among class 3 patients, 63.1% had positive SARS-CoV-2 serology only and 33.8% had both serologic confirmation and positive RT-PCR results.

Top

Discussion

Initial reports of MIS-C patients described varied clinical signs and symptoms at initial evaluation, but most cases included features of shock, cardiac dysfunction, gastrointestinal symptoms, significantly elevated markers of inflammation and cardiac damage, and positive test results for SARS-CoV-2 by serology (3,6–8). Because the case definition is nonspecific and confirmatory laboratory testing does not exist, it might be difficult to distinguish MIS-C from other conditions with overlapping clinical manifestations such as severe acute COVID-19 and Kawasaki disease (9). Latent class analysis is particularly well-suited to describe differing manifestations of a novel clinical syndrome. It divides patients into groups that might have been previously unrecognized, based on shared characteristics, allowing for an unbiased determination of disease manifestations. Patients identified in class 1 had little overlap with acute COVID-19 or Kawasaki disease, whereas patients in class 2 had clinical and laboratory manifestations that overlapped with acute COVID-19. This overlap might result from the development of MIS-C soon after symptomatic acute COVID-19 illness. However, the presence of isolated severe acute COVID-19 illness cannot be ruled out in some of these patients. Patients in class 3 generally seemed to have less severe MIS-C illness and clinical manifestations that overlapped with Kawasaki disease, and distinguishing class 3 patients from those with true Kawasaki disease could be difficult (4). As the COVID-19 pandemic spreads, and more children are exposed to SARS-CoV-2 with subsequent seroconversion, patients with Kawasaki disease might be misidentified as MIS-C because of an incidental finding of antibodies to SARS-CoV-2.

Overall, the age distribution of the patients in this analysis is similar to that described elsewhere, but there are differences in the clinical manifestations and laboratory findings, perhaps due to differences in inclusion criteria (6,7). Increases in COVID-19 incidence might result in increased occurrence of MIS-C which might not be apparent immediately because of the 2–4-week delay in the development of MIS-C after acute SARS-CoV-2 infection (8). The proportion of Hispanic, black, and white MIS-C patients with obesity is slightly higher than that reported in the general pediatric population. Hispanic and black patients accounted for the largest proportion (73.6%) of reported MIS-C patients. Acute COVID-19 has been reported to disproportionately affect Hispanics and blacks (10). Long-standing inequities in the social determinants of health, such as housing, economic instability, insurance status, and work circumstances of patients and their family members have systematically placed social, racial, and ethnic minority populations at higher risk for COVID-19 and more severe illness, possibly including MIS-C.**

The findings in this report are subject to at least four limitations. First, there is a possibility of case identification and reporting bias, including variability in diagnosis, testing, and management of patients by different jurisdictions. Second, inconsistency in completion of case report forms, with some patients still hospitalized at the time of reporting, might have affected data completeness (e.g., race and ethnicity were not reported for 18.9% of cases). Third, access to SARS-CoV-2 testing at the time of onset might have varied by regions, hospitals, and time. Finally, CDC’s case definition was broad, with the intention of being more inclusive, which might have led to the unintentional inclusion of patients whose illnesses overlapped with acute COVID-19 and Kawasaki disease.

As the COVID-19 pandemic continues, with the number of cases increasing in many jurisdictions, health care providers should continue to monitor patients to identify children with a hyperinflammatory syndrome with shock and cardiac involvement. Suspected MIS-C patients should be reported to local and state health departments. Distinguishing patients with MIS-C from those with acute COVID-19 and other hyperinflammatory conditions is critical for early diagnosis and appropriate management. It is also critical for monitoring potential adverse events of a COVID-19 vaccine when one becomes widely available. Studies to define the clinical and laboratory characteristics of MIS-C should continue, including identification of parameters that will help distinguish the illness from other similar conditions.

Top

Acknowledgments

Xandy Peterson Pompa, Arizona Department of Health Services; Robert Deener, Berkley County Health Department; Brooke Bregman, Sebastian Chavez, Ellora Karmarkar, John J Openshaw, Hilary E Rosen, Rob Schechter, California Department of Public Health; Joann Gruber, CDC; Lea Kendrick, Children’s Healthcare of Atlanta; Nisha Alden, Isaac Armistead, Alexis Burakoff, Rachel Herlihy, Breanna Kawasaki, Allison Mahon, Jackie West-Denning, Colorado Department of Public Health and Environment; Christopher L. Carroll, Connecticut Children’s Medical Center; Lynn Sosa, Connecticut Department of Public Health; Paula Eggers, Division of Public Health, Delaware Health and Social Services; Douglas County Health Department and Two Rivers Public Health Department; Andi L. Shane MD, Preeti Jaggi, Christina A. Rostad, Matt Linam, Emory University School of Medicine and Children’s Healthcare of Atlanta; Laurel Harduar Morano, Epidemic Intelligence Service, CDC; Melissa Tobin-D’Angelo, Siri Wilson, Kristina Lam, Georgia Department of Public Health; Hawaii Department of Health; Caitlin Pedati, Oluwakemi Oni, John Satre, Iowa Department of Public Health; Ngozi Ezike, Illinois Department of Public Health; Lindsay Weaver, Sally Hallyburton, Indiana State Department of Health; Justin Blanding, Kansas Department of Health and Environment; Kathy Terry, Janiper Kwak, Island Peer Review Organization, Inc; Stacy Davidson, Amanda Hunt, Kevin Spicer, Kentucky Department of Public Health; Moon Kim, Susan Hathaway, Candace Gragnani, Los Angeles County Department of Public Health; Julie Hand, Louisiana Department of Health; Catherine M Brown, Meagan Burns, Allison L Neeson, Catherine Reilly, Bureau of Infectious Disease and Laboratory Sciences, Massachusetts Department of Public Health; David Blythe, Monique Duwell, John Sweitzer, Brian Schuh, Anna C. Sick-Samuels, Maryland Department of Health; Justin Henderson, Sally Bidol, Cole Burkholder, Bureau of Epidemiology, Michigan Department of Health and Human Services; Kate Cleavinger, Bureau of Communicable Disease Control and Prevention, Missouri Department of Health and Senior Services; Cindy Allard, Mississippi State Department of Health; Jenna Lifshitz, Jihong Yao, Stella Tsai, New Jersey Department of Health; Janis Gonzales, Joseph T. Hicks, Annaliese Mayette, New Mexico Department of Health; Marcus Friedrich, New York State Department of Health; Mike Antwi, Robert Arciuolo, Dena Bushman, Vennus Ballen, Jennifer Baumgartner, Marie Dorsinville, Daniel Eiras, Ana Maria Fireteanu, Kelsey L. Kepler, Emily McGibbon, Natasha McIntosh, Christina Ng, Stephanie Ngai, Rachel Paneth-Pollak, Jyotsna Ramachandran, Emma Ruderman, Julia Schillinger, Aparna Shankar, Amita Toprani, Ann Winters, New York City Department of Health and Mental Hygiene; Erica Wilson, Lana Deyneka, North Carolina Department of Health and Human Services; Ohio Department of Health; Ozair Naqvi, Tamela Hamilton, Oklahoma State Department of Health; Melissa Sutton, Oregon Health Authority; Kimberly Kline, Pendleton County Health Department; Kumar Nalluswami, Allison Longenberger, Jonah M Long, Sharon M. Watkins, Bureau of Epidemiology, Pennsylvania Department of Health; Amanda Hartley, Cassandra Jones, Tennessee Department of Health; Jonathan M Kolsin, Texas Department of State Health Services; Elizabeth Groenweghe, Unified Government of Wyandotte County and Kansas City Public Health Department; Angela C. Dunn, Bree Barbeau, Rachelle Boulton, Utah Department of Health; Azizul Islam, Andrea Young, Heather Buysse, Nancy Bryant, Julia Dorsey, Stephanie Kellner, Sara Naramore, Nicole Sullivan, Virginia Department of Health; Kossia Dassie, Preetha Iyengar, Washington D.C. Department of Health; Marisa A D’Angeli, Lindsay M Horn, Washington State Department of Health; Lindsey Mason, West Virginia Department of Health and Human Resources; Thomas Haupt, Wisconsin Department of Health Services; Thomas Murray, Christina Murdzek, Kathy Krechevsky, Yale New Haven Children’s Hospital.

Top

Corresponding author: Shana Godfred-Cato, nzt6@cdc.gov.

Top

1CDC COVID-19 Response Team; 2Oak Ridge Institute for Science and Education; 3New York City Department of Health and Mental Hygiene; 4New York State Department of Health; 5New Jersey Department of Health; 6Epidemic Intelligence Service, Prevention and Health Promotion Administration, Maryland Department of Health; 7Massachusetts Department of Public Health; 8Pennsylvania Department of Health; 9Louisiana Department of Health; 10Illinois Department of Public Health; 11Minnesota Department of Health; 12Florida Department of Health; 13Career Epidemiology Field Officer Program, CDC.

Top

All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.

Top


* https://www.rcpch.ac.uk/sites/default/files/2020-05/COVID-19-Paediatric-multisystem-%20inflammatory%20syndrome-20200501.pdf.

† The MIS-C case definition included a patient aged <21 years with fever, laboratory evidence of inflammation, and evidence of clinically severe illness requiring hospitalization, with multisystem organ involvement (cardiovascular, dermatologic, gastrointestinal, hematologic, neurologic, renal, or respiratory) who tested positive for SARS-CoV-2 or had exposure to COVID-19. https://www.cdc.gov/mis-c/hcp/.

§ Kawasaki disease is an acute febrile illness of unknown cause, primarily affecting children, and associated with fever, rash, conjunctivitis, redness in the mouth, cracked lips, and swollen lymph nodes, feet, and hands.

https://www.cdc.gov/obesity/data/childhood.html.

** https://www.cdc.gov/coronavirus/2019-ncov/community/health-equity/race-ethnicity.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fneed-extra-precautions%2Fracial-ethnic-minorities.html.

Top

References

  1. Riphagen S, Gomez X, Gonzalez-Martinez C, Wilkinson N, Theocharis P. Hyperinflammatory shock in children during COVID-19 pandemic. Lancet 2020;395:1607–8. CrossRef PubMed
  2. Toubiana J, Poirault C, Corsia A, et al. Outbreak of Kawasaki disease in children during COVID-19 pandemic in Paris, France: prospective observational study. BMJ 2020;369:m2094. CrossRef PubMed
  3. Belhadjer Z, Méot M, Bajolle F, et al. Acute heart failure in multisystem inflammatory syndrome in children (MIS-C) in the context of global SARS-CoV-2 pandemic. Circulation 2020. E-pub May 17, 2020.
  4. Verdoni L, Mazza A, Gervasoni A, et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. Lancet 2020;395:1771–8. CrossRef PubMed
  5. Linzer DA, Lewis JB. poLCA: An R package for polytomous variable latent class analysis. J Stat Softw 2011;42:1–29. CrossRef
  6. Dufort EM, Koumans EH, Chow EJ, et al.; New York State and CDC Multisystem Inflammatory Syndrome in Children Investigation Team. Multisystem inflammatory syndrome in children in New York State. N Engl J Med 2020;383:347–58. CrossRef PubMed
  7. Whittaker E, Bamford A, Kenny J, et al.; PIMS-TS Study Group and EUCLIDS and PERFORM Consortia. Clinical characteristics of 58 children with a pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2. JAMA 2020;324:259–69. CrossRef PubMed
  8. Feldstein LR, Rose EB, Horwitz SM, et al.; Overcoming COVID-19 investigators and the CDC COVID-19 Response Team. Multisystem inflammatory syndrome in U.S. children and adolescents. N Engl J Med 2020;383:334–46. CrossRef PubMed
  9. Bialek S, Gierke R, Hughes M, McNamara LA, Pilishvili T, Skoff T; CDC COVID-19 Response Team. Coronavirus disease 2019 in children—United States, February 12–April 2, 2020. MMWR Morb Mortal Wkly Rep 2020;69:422–6. CrossRef PubMed
  10. Stokes EK, Zambrano LD, Anderson KN, et al. Coronavirus disease 2019 case surveillance—United States, January 22–May 30, 2020. MMWR Morb Mortal Wkly Rep 2020;69:759–65. CrossRef PubMed

Top

Return to your place in the textFIGURE. Geographic distribution of 570 reported cases of multisystem inflammatory syndrome in children — United States, March–July 2020
The figure is a map of the United States showing the geographic distribution of 570 reported cases of multisystem inflammatory syndrome in children during March–July 2020.

Abbreviations: DC = District of Columbia; NYC = New York City.

Top

TABLE 1. Characteristics of patients (N = 570) reported with multisystem inflammatory syndrome in children (MIS–C) — United States, March–July 2020Return to your place in the text
Characteristic No. (%) p value
Total (N = 570) Latent class analysis group*
Class 1 (n = 203) Class 2 (n = 169) Class 3 (n = 198)
Sex
Female 254 (44.6%) 87 (42.9%) 81 (47.9%) 86 (43.4%) 0.57
Male 316 (55.4%) 116 (57.1%) 88 (52.1%) 112 (56.6%)
Age (yrs), median (IQR) 8 (4–12) 9 (6–13) 10 (5–15) 6 (3–10) <0.01
Race/Ethnicity
Hispanic 187 (40.5%) 62 (36.9%) 62 (46.6%) 63 (39.1%) 0.03
Black, non–Hispanic 153 (33.1%) 66 (39.3%) 39 (29.3%) 48 (29.8%)
White, non–Hispanic 61 (13.2%) 22 (13.1%) 15 (11.3%) 24 (14.9%)
Other 26 (5.6%) 8 (4.8%) 6 (4.5%) 12 (7.5%)
Multiple 18 (3.9%) 9 (5.4%) 5 (3.8%) 4 (2.5%)
Asian 13 (2.8%) 1 (0.6%) 3 (2.3%) 9 (5.6%)
American Indian/Alaskan Native 3 (0.6%) 0 (0.0%) 3 (2.3%) 0 (0.0%)
Native Hawaiian/Pacific Islander 1 (0.2%) 0 (0.0%) 0 (0.0%) 1 (0.6%)
Unknown 108 (─) 35 (─) 36 (─) 37 (─)
Outcome
Died 10 (1.8%) 1 (0.5%) 9 (5.3%) 0 (0.0%) <0.01
Days in hospital, median (IQR) 6 (4–9) 8 (6–11) 6 (4–10) 5 (4–8) <0.01
1 16 (3.2%) 3 (1.8%) 3 (2.0%) 10 (5.4%) <0.01
2–7 304 (60.2%) 86 (50.3%) 87 (58.8%) 131 (70.4%)
8–14 149 (29.5%) 66 (38.6%) 41 (27.7%) 42 (22.6%)
≥15 36 (7.1%) 16 (9.4%) 17 (11.5%) 3 (1.6%)
Missing 65 (─) 32 (─) 21 (─) 12 (─)
ICU admission 364 (63.9%) 171 (84.2%) 105 (62.1%) 88 (44.4%) <0.01
Days in ICU, median (IQR) 5 (3–7) 5 (4–7) 6 (3–9) 3 (2–5) <0.01
Underlying medical conditions <0.01
Obesity 146 (25.6%) 60 (29.6%) 49 (29.0%) 37 (18.7%) 0.02
Chronic lung disease 48 (8.4%) 18 (8.9%) 17 (10.1%) 13 (6.6%) 0.46
Clinical characteristic
No. of organ systems involved
2–3 80 (14.0%) 6 (3.0%) 24 (14.2%) 50 (25.3%) <0.01
4–5 351 (61.6%) 98 (48.3%) 113 (66.9%) 140 (70.7%)
≥6 139 (24.4%) 99 (48.8%) 31 (18.3%) 9 (4.5%)
Days with fever, median (IQR) 5 (3–6) 5 (3–6) 5 (3–6) 5 (3–6) 0.81
Kawasaki disease† 28 (4.9) 10 (4.9) 5 (3.0) 13 (6.6) 0.30
Organ system involvement
Gastrointestinal 518 (90.9%) 198 (97.5%) 146 (86.4%) 174 (87.9%) <0.01
Abdominal pain 353 (61.9%) 163 (80.3%) 83 (49.1%) 107 (54.0%) <0.01
Vomiting 352 (61.8%) 145 (71.4%) 95 (56.2%) 112 (56.6%) <0.01
Diarrhea 303 (53.2%) 124 (61.1%) 79 (46.7%) 100 (50.5%) 0.01
Cardiovascular 493 (86.5%) 203 (100.0%) 143 (84.6%) 147 (74.2%) <0.01
Shock 202 (35.4%) 154 (75.9%) 48 (28.4%) 0 (0.0%) <0.01
Elevated troponin 176 (30.9%) 93 (45.8%) 43 (25.4%) 40 (20.2%) <0.01
Elevated BNP or NT–proBNP 246 (43.2%) 105 (51.7%) 77 (45.6%) 64 (32.3%) <0.01
Congestive heart failure 40 (7.0%) 21 (10.3%) 14 (8.3%) 5 (2.5%) 0.02
Cardiac dysfunction§ 207 (40.6%) 105 (55.3%) 64 (46.0%) 38 (21.0%) <0.01
Myocarditis 130 (22.8%) 62 (30.5%) 36 (21.3%) 32 (16.2%) 0.01
Coronary artery dilatation or aneurysm§ 95 (18.6%) 40 (21.1%) 22 (15.8%) 33 (18.2%) 0.49
Hypotension 282 (49.5%) 162 (79.8%) 75 (44.4%) 45 (22.7%) <0.01
Pericardial effusion§ 122 (23.9%) 55 (28.9%) 32 (23.0%) 35 (19.3%) 0.01
Mitral regurgitation§ 130 (25.5%) 68 (35.8%) 30 (21.6%) 32 (17.7%) <0.01
Dermatologic and mucocutaneous 404 (70.9%) 156 (76.8%) 87 (51.5%) 161 (81.3%) <0.01
Rash 315 (55.3%) 121 (59.6%) 70 (41.4%) 124 (62.6%) <0.01
Mucocutaneous lesions 201 (35.3%) 70 (34.5%) 42 (24.9%) 89 (44.9%) <0.01
Conjunctival injection 276 (48.4%) 118 (58.1%) 54 (32.0%) 104 (52.5%) <0.01
Hematologic 421 (73.9%) 161 (79.3%) 130 (76.9%) 130 (65.7%) <0.01
Elevated D–dimer 344 (60.4%) 136 (67.0%) 104 (61.5%) 104 (52.5%) 0.01
Thrombocytopenia 176 (30.9%) 84 (41.4%) 45 (26.6%) 47 (23.7%) <0.01
Lymphopenia 202 (35.4%) 82 (40.4%) 60 (35.5%) 60 (30.3%) 0.11
Respiratory** 359 (63.0%) 155 (76.4%) 129 (76.3%) 75 (37.9%) <0.01
Cough 163 (28.6%) 51 (25.1%) 67 (39.6%) 45 (22.7%) <0.01
Shortness of breath 149 (26.1%) 66 (32.5%) 59 (34.9%) 24 (12.1%) <0.01
Chest pain or tightness 66 (11.6%) 33 (16.3%) 24 (14.2%) 9 (4.5%) 0.01
Pneumonia†† 110 (19.3%) 47 (23.2%) 62 (36.7%) 1 (0.5%) <0.01
ARDS 34 (6.0%) 14 (6.9%) 17 (10.1%) 3 (1.5%) <0.01
Pleural effusion§§ 86 (15.8%) 49 (24.7%) 29 (18.4%) 8 (4.2%) <0.01
Neurologic 218 (38.2%) 107 (52.7%) 70 (41.4%) 41 (20.7%) <0.01
Headache 186 (32.6%) 90 (44.3%) 63 (37.3%) 33 (16.7%) <0.01
Renal 105 (18.4%) 77 (37.9%) 28 (16.6%) 0 (0.0%) <0.01
Acute kidney injury 105 (18.4%) 77 (37.9%) 28 (16.6%) 0 (0.0%) <0.01
Other
Periorbital edema 27 (4.7%) 13 (6.4%) 5 (3.0%) 9 (4.5%) 0.32
Cervical lymphadenopathy >1.5 cm diameter 76 (13.3%) 28 (13.8%) 18 (10.7%) 30 (15.2%) 0.43
SARS COV–2 testing
Any laboratory test done 565 (99.1%) 200 (98.5%) 169 (100.0%) 196 (99.0%) 0.39
Any positive laboratory test¶¶ (% among tested) 565 (100.0%) 200 (100.0%) 169 (100.0%) 196 (100.0%) NA
PCR positive/Serology negative, not done, or missing*** 147 (25.8%) 1 (0.5%) 142 (84.0%) 4 (2.0%) <0.01
Serology positive/PCR negative††† 263 (46.1%) 138 (68.0%) 0 (0.0%) 125 (63.1%) <0.01
PCR positive/Serology positive 155 (27.2%) 61 (30.0%) 27 (16.0%) 67 (33.8%) <0.01
Epidemiologic link only, with no testing 5 (0.9%) 3 (1.5%) 0 (0.0%) 2 (1.0%) <0.01
Treatment§§§
IVIG¶¶¶ 424 (80.5%) 174 (87.9%) 96 (62.7%) 154 (87.5%) <0.01
Steroids 331 (62.8%) 145 (73.2%) 80 (52.3%) 106 (60.2%) <0.01
Antiplatelet medication 309 (58.6%) 113 (57.1%) 69 (45.1%) 127 (72.2%) <0.01
Anticoagulation medication 233 (44.2%) 92 (46.5%) 76 (49.7%) 65 (36.9%) 0.03
Vasoactive medications 221 (41.9%) 129 (65.2%) 64 (41.8%) 28 (15.9%) <0.01
Respiratory support, any 201 (38.1%) 104 (52.5%) 79 (51.6%) 18 (10.2%) <0.01
Intubation and mechanical ventilation 69 (13.1%) 37 (18.7%) 30 (19.6%) 2 (1.1%) <0.01
Immune modulators 119 (22.6%) 52 (26.3%) 34 (22.2%) 33 (18.8%) 0.18
Dialysis 2 (0.4%) 0 (0.0%) 2 (1.3%) 0 (0.0%) 0.08

Abbreviations: ARDS = acute respiratory distress syndrome; BNP = brain natriuretic peptide; ICU = intensive care unit; IQR = interquartile range; IVIG = intravenous immune globulin; NT-proBNP = N-terminal pro b-type natriuretic peptide; PCR = polymerase chain reaction.
* Latent class analysis (LCA) is a statistical modeling technique in which observations can be classified into latent classes based on their underlying similarities. Variables that are associated with MIS-C clinical manifestation were selected as indicator variables and included in the LCA model.
† Patient had fever, rash, conjunctival injection, cervical lymphadenopathy >1.5 cm diameter, and mucocutaneous lesions.
§ Percentages calculated among 510 persons with an echocardiogram performed.
Thrombocytopenia was defined as a platelet count of less than 150 x 103 per μl or if thrombocytopenia was checked on the case-report form. Lymphopenia was defined as a lymphocyte count of <4,500 cells per μl for infants aged <8 months, or less than 1,500 cells per ml for persons aged ≥8 months.
**Among 359 with respiratory organ system involvement, 324 (90%) also had cardiovascular system involvement.
†† Information about pneumonia was collected on the case report form under signs and symptoms, complications, or chest imaging.
§§ Percentages calculated among 545 persons with either an echocardiogram or chest imaging performed.
¶¶ Eight cases had a positive SARS CoV–2 antigen test result, among whom three were also positive by both PCR and serology, one was positive by PCR alone, and one was positive by serology alone.
*** Among 147 cases with a positive PCR result without a positive serologic test result, 10 had a negative serologic test, and the remaining had unknown serologic testing.
††† Among 263 cases with positive serologic test result without a positive PCR result, 254 had a negative PCR result, and the remaining had unknown PCR testing.
§§§ Percentages calculated among 527 persons who received treatment.
¶¶¶ 73 received a second dose of IVIG.

Top

TABLE 2. Reported serum laboratory values for multisystem inflammatory syndrome in children (MIS-C) cases (N = 570), by latent class analysis (LCA) group* — United States, March–July 2020Return to your place in the text
LCA class 1 LCA class 2 LCA class 3 p-value
 Laboratory test No. Median IQR No. Median IQR No. Median IQR
Fibrinogen, peak (mg/dL) 151 557 (449–713) 87 566 (430–662) 105 546 (426–681) 0.67
D-dimer, peak (mg/L) 158 3.0 (1.6–4.9) 106 2.6 (1.2–5.1) 128 1.7 (0.8–3.2) <0.01
Troponin, peak (ng/mL) 162 0.09 (0.02–0.48) 109 0.05 (0.01–0.30) 130 0.01 (0.01–0.08) <0.01
BNP, peak (pg/mL) 53 1,321 (414–2,528) 30 198 (76–927) 25 182 (30–616) <0.01
proBNP, peak (ng/L) 103 4,700 (1,261–13,646) 68 1,503 (247–6,846) 92 507 (176–2,153) <0.01
start highlightCRP, peak (mg/L)end highlight 166 21 (14–29) 122 16 (9–25) 144 14 (6–23) <0.01
Ferritin, peak (ng/mL) 159 610 (347–1,139) 108 422 (207–825) 132 242 (116–466) <0.01
IL-6, peak (pg/mL) 54 65 (24–258) 27 41 (21–131) 29 69 (7–118) 0.24
Platelets, nadir (103 cells/μl) 115 131 (102–203) 76 172 (103–245) 68 150 (113–237) 0.15
Lymphocytes, nadir (cells/μl) 72 695 (400–1,093) 49 1,200 (790–2,025) 42 1,420 (723–2,250) <0.01

Abbreviations: BNP = brain natriuretic peptide; CRP = C-reactive protein; IL-6 = Interleukin-6; IQR = interquartile range.
* Latent class analysis (LCA) is a statistical modeling technique in which observations can be classified into latent classes based on their underlying similarities. Variables that are associated with MIS-C clinical manifestation were selected as indicator variables and included in the LCA model.

Top


Suggested citation for this article: Godfred-Cato S, Bryant B, Leung J, et al. COVID-19–Associated Multisystem Inflammatory Syndrome in Children — United States, March–July 2020. MMWR Morb Mortal Wkly Rep 2020;69:1074–1080. DOI: http://dx.doi.org/10.15585/mmwr.mm6932e2.

MMWR and Morbidity and Mortality Weekly Report are service marks of the U.S. Department of Health and Human Services.
Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.
References to non-CDC sites on the Internet are provided as a service to MMWR readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of pages found at these sites. URL addresses listed in MMWR were current as of the date of publication.

All HTML versions of MMWR articles are generated from final proofs through an automated process. This conversion might result in character translation or format errors in the HTML version. Users are referred to the electronic PDF version (https://www.cdc.gov/mmwr) and/or the original MMWR paper copy for printable versions of official text, figures, and tables.

Questions or messages regarding errors in formatting should be addressed to mmwrq@cdc.gov.

View Page In: PDF [173K]